On Thursday, Dex Media Inc (NASDAQ:DXM)’s shares declined -46.82% to $1.42.
Dex Media Inc (DXM) declared the launch of its new customer relationship administration platform, DexLnk.
DexLnk offers small and medium-sized businesses a free platform for managing all customer data and communications in one place. The pilot product assists Dex Media clients build and manage customer lists, accept appointments using an online calendar, and send customers confirmations and reminders via email and text messaging. In addition, the tool, which is fully optimized for mobile devices, enables business owners to send special offers based on customer preferences, and monitor the results of their marketing programs from a comprehensive dashboard. Additional features and functionality are accessible at different price tiers.
Dex Media, Inc. provides local marketing solutions to business clients in the United States. The company publishes yellow page directories that provide various paid advertising options, counting listing options; in-column advertisement options that comprise bolding, special fonts, color, and special features, such as logos; display advertising options, which allows businesses to comprise information, illustrations, photographs, and logos; and specialty advertising options that allow businesses to target specific consumers.
iCAD Inc (NASDAQ:ICAD)’s shares dropped -41.76% to $4.63.
iCAD Inc (ICAD) declared the launch of an improved eBx® Institute counting a new online learning and support platform for Xoft® Electronic Brachytherapy (eBx) System® users. eBx Institute will offer healthcare providers access to training modules and educational resources to support the treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers using the Xoft System. The web-based solution provides an array of on-demand, self-paced learning programs, counting instructional courses and reference materials.
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy.
At the end of Thursday’s trade, Varonis Systems Inc (NASDAQ:VRNS)‘s shares dipped -24.78% to $20.07.
Varonis Systems Inc (VRNS) declared that Chief Executive Officer Yaki Faitelson and Chief Financial Officer Gili Iohan will present at the Jefferies 2015 Global Technology, Media and Telecom Conference in Miami.
Their presentation is planned for Tuesday, May 12, 2015 at 11:30 a.m. EDT. The audio presentation will be webcast live and will be accessible by visiting the “Investor Relations” section of the company’s website at www.varonis.com. The webcast will be archived on the company’s website for a limited time following the conference.
Varonis Systems, Inc. provides software platform for enterprises to map, analyze, manage, and migrate their unstructured data. Its Metadata Framework technology platform extracts critical metadata, or data about data, from an organization’s IT infrastructure and uses this contextual information to map functional relationships among employees, data objects, content, and usage.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), ended its Thursday’s trading session with -19.71% loss, and closed at $14.50.
Sucampo Pharmaceuticals, Inc. (SCMP) declared that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for cobiprostone, a locally acting chloride channel activator, for the prevention of oral mucositis. The FDA has also accepted the company’s Investigational New Drug (IND) application to initiate a phase 2 clinical trial of cobiprostone for the prevention of oral mucositis in patients suffering with head and neck cancer receiving concurrent radiation and chemotherapy.
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs in the Americas, Europe, and Asia. It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders, in addition to other therapeutic applications of drug technologies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
